This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

1 hour ago 1

Jonathan Ponciano, The Motley Fool

Sat, March 21, 2026 astatine 5:25 PM CDT 4 min read

Kynam Capital Management reduced its presumption successful CG Oncology (NASDAQ:CGON), selling 1,059,375 shares successful the 4th fourth for an estimated $43.84 cardinal based connected quarterly mean pricing, according to a February 17, 2026, SEC filing.

According to a filing with the Securities and Exchange Commission dated February 17, 2026, Kynam Capital Management sold 1,059,375 shares of CG Oncology during the 4th quarter. The estimated transaction worth was $43.84 million, calculated utilizing the period's mean closing price. After the sale, the money held 945,830 shares, valued astatine $39.27 cardinal astatine quarter-end. The nett presumption change, reflecting some trading and terms effects, was $41.50 million.

The simplification brings CG Oncology to 2.51% of Kynam Capital’s 13F reportable AUM, down from 6.0% the anterior quarter.
Top holdings aft the filing:
- NASDAQ:COGT: $218.99 cardinal (14.3% of AUM)
- NASDAQ:VERA: $173.85 cardinal (11.3% of AUM)
- NASDAQ:SNDX: $169.15 cardinal (11.0% of AUM)
- NASDAQ:CLDX: $161.42 cardinal (10.5% of AUM)
- NASDAQ:PCVX: $134.84 cardinal (8.8% of AUM)
As of Friday, CG Oncology shares were priced astatine $65.08, up 135% implicit the past twelvemonth and good surpassing the S&P 500’s astir 15% summation successful the aforesaid period.

Metric

Value

Market Capitalization	$5.5 billion
Revenue (TTM)	$4 million
Net Income (TTM)	($160.1 million)
Price (as of Friday)	$65.08

CG Oncology develops and commercializes cretostimogene, a bladder-sparing therapeutic campaigner for high-risk non-muscle invasive bladder crab unresponsive to Bacillus Calmette Guerin (BCG) therapy.
The steadfast operates arsenic a clinical-stage biopharmaceutical company, generating gross chiefly done objective improvement activities and imaginable aboriginal merchandise commercialization.
It targets oncology healthcare providers and patients with high-risk bladder cancer, focusing connected those with constricted attraction options aft BCG therapy failure.

CG Oncology, Inc. is simply a biotechnology institution specializing successful innovative therapies for bladder cancer, with a strategical absorption connected addressing unmet aesculapian needs successful high-risk diligent populations. The institution leverages objective expertise and a targeted merchandise pipeline to presumption itself wrong the oncology therapeutics market. Its pb candidate, cretostimogene, aims to supply a differentiated, bladder-sparing attraction option, enhancing its competitory borderline successful the evolving biopharmaceutical landscape.

CG Oncology has delivered precisely the benignant of show that mightiness unit an capitalist to see managing exposure. Shares are up much than 130% implicit the past year, fueled by increasing excitement astir cretostimogene and a packed slate of upcoming objective milestones, including Phase 3 information expected successful the archetypal fractional of 2026. At the aforesaid time, this is inactive a pre-commercial concern generating conscionable astir $4 cardinal successful yearly gross portion posting a nett nonaccomplishment of astir $161 million.

To beryllium fair, the institution does person a beardown equilibrium sheet, with much than $740 cardinal successful currency astatine year-end and person to $900 cardinal much recently, giving it runway into 2029. But the valuation is inactive being driven astir wholly by aboriginal objective success, and that mightiness beryllium wherefore Kynam decided to fastener successful immoderate gains past quarter. The firm’s aboriginal show surely hinges connected upcoming proceedings readouts, and though affirmative information could assistance substance the surge, there’s besides the hazard that investors person priced successful immoderate beauteous lofty expectations.

Read Entire Article